Enliven Therapeutics Statistics
Share Statistics
Enliven Therapeutics has 49.07M
shares outstanding. The number of shares has increased by 4.18%
in one year.
| Shares Outstanding | 49.07M |
| Shares Change (YoY) | 4.18% |
| Shares Change (QoQ) | 0.3% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,951 |
| FTD / Avg. Volume | 0.96% |
Short Selling Information
The latest short interest is 6.96M, so 14.19% of the outstanding
shares have been sold short.
| Short Interest | 6.96M |
| Short % of Shares Out | 14.19% |
| Short % of Float | 22.16% |
| Short Ratio (days to cover) | 28.86 |
Valuation Ratios
The PE ratio is -11.9 and the forward
PE ratio is -6.15.
Enliven Therapeutics's PEG ratio is
1.99.
| PE Ratio | -11.9 |
| Forward PE | -6.15 |
| PS Ratio | 0 |
| Forward PS | 10 |
| PB Ratio | 3.42 |
| P/FCF Ratio | -14.46 |
| PEG Ratio | 1.99 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Enliven Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.99,
with a Debt / Equity ratio of 0.
| Current Ratio | 19.99 |
| Quick Ratio | 19.99 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,435,870.97 |
| Employee Count | 62 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -232K |
| Effective Tax Rate | 0.26% |
Stock Price Statistics
The stock price has increased by -26.98% in the
last 52 weeks. The beta is 1.1, so Enliven Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.1 |
| 52-Week Price Change | -26.98% |
| 50-Day Moving Average | 18.8 |
| 200-Day Moving Average | 22.52 |
| Relative Strength Index (RSI) | 40.82 |
| Average Volume (20 Days) | 306,779 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -104.55M |
| Net Income | -89.02M |
| EBITDA | -88.47M |
| EBIT | -88.79M |
| Earnings Per Share (EPS) | -1.89 |
Full Income StatementBalance Sheet
The company has 124.12M in cash and 0 in
debt, giving a net cash position of 124.12M.
| Cash & Cash Equivalents | 124.12M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -243.47M |
| Total Assets | 302.57M |
| Working Capital | 280.35M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -73.19M
and capital expenditures -44K, giving a free cash flow of -73.24M.
| Operating Cash Flow | -73.19M |
| Capital Expenditures | -44K |
| Free Cash Flow | -73.24M |
| FCF Per Share | -1.56 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
